Navigation Links
New national clinical trials network for neurological disorders to foster cutting-edge treatments
Date:9/12/2012

DALLAS Sept. 13, 2012 UT Southwestern Medical Center's expertise in neurology has earned it a place in an innovative national clinical trials network that will make it easier to test promising treatments for patients with brain, muscle and nerve disorders.

UT Southwestern, one of 25 sites selected for the National Institute of Neurological Disorders and Stroke's (NINDS) new Network for Excellence in Neuroscience Clinical Trials, is the only participating medical center in Texas and its bordering states.

The network, known as NeuroNEXT, represents a unique model of clinical trials for brain diseases. By creating a shared infrastructure and institutional review board, institute officials said they expect to minimize the time and expense of studies while making new treatments available to patients more quickly.

"We want to bring the fruits of discovery in the laboratory as quickly as we can to the patients who need them," said Dr. Mark Goldberg, chairman of neurology and neurotherapeutics at UT Southwestern and a co-principal investigator for the project. "It is more efficient to have a well-organized team in place, allowing us to test one therapy after the next."

UT Southwestern is expected to receive $1.4 million in NINDS support over the next seven years for its role in the network.

Dr. Petra Kaufmann, the NINDS' associate director for clinical research, said UT Southwestern was an excellent candidate for NeuroNEXT because of the medical center's breadth of multidisciplinary expertise across the subspecialties of neurology, neurological surgery and neuroradiology for pediatrics and adults. She also cited the medical center's clinical research experience and access to a large patient population.

"An important piece was the strength in the coordination and collaboration of the investigators," Dr. Kaufmann said. "UT Southwestern also is built on solid basic science enterprise and has translational research capacity. This really was a very good fit."

NeuroNEXT's first clinical trial is designed to identify biomarkers for spinal muscular atrophy (SMA), a motor-neuron disease that causes progressive weakness and respiratory disease. It is the most common genetic cause of death in infants, and those with the most aggressive form of the disease often die before they are 2 years old. There currently is no effective treatment or cure.

UT Southwestern's participation in the trial includes Dr. Susan Iannaccone, a NeuroNEXT co-principal investigator who treats one of the nation's largest populations of spinal muscular atrophy patients. In 2000, she set up one of the disease's first national clinical trial groups, which was expanded from five sites to 15 through two rounds of funding from the National Institutes of Health.

Although successful, that earlier network required expensive and time-consuming planning and execution, said Dr. Iannaccone, professor of pediatrics and of neurology and neurotherapeutics at UT Southwestern. Centralizing those efforts through NeuroNEXT, she said, will allow investigators to focus on research and treatment.

"This means the future is brighter for our patients," said Dr. Iannaccone, who also is director of pediatric neurology at Children's Medical Center. "The faster you can test drugs, the faster you can find out if they work."


'/>"/>
Contact: Jeff Carlton
jeffrey.carlton@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert  

Related medicine news :

1. Hospital for Special Surgery investigators receive National Football League grant for PRP research
2. Lights off? International experts call attention to dangers of exposure to light at night
3. Curbing Suicide Now a National Priority, U.S. Says
4. National deficit outlook unchanged under Obama: UMD policy analysis
5. National survey of economists uncovers vast gender gap in policy views
6. Queens University Belfast wins national environment award
7. Canada needs national approach to protect against drug shortages
8. ACP physician wins national award for internal medicine education
9. Researchers awarded National Cancer Institute grants aimed at answering provocative questions
10. International academic publishers join Committee on Publication Ethics
11. National Hartford Centers of Gerontological Nursing Excellence awards new fellows, scholars
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New national clinical trials network for neurological disorders to foster cutting-edge treatments
(Date:5/4/2016)... , ... May 04, 2016 , ... Nike Rugby Camp's ... rugby in San Diego. Willis, founder of Elite Rugby Camps and current Nike Camp ... players every year since 2009. , “I’m excited for our eighth summer here ...
(Date:5/4/2016)... ... 04, 2016 , ... Hight-Doland Insurance Agency’s new community involvement program which serves ... Big Sisters of Southwest Louisiana to help provide positive mentoring for local youth. Donations ... Big Sisters of Southwest Louisiana has been helping to guide the area’s youth for ...
(Date:5/4/2016)... ... May 04, 2016 , ... May kicked off with Melanoma ... United States. Dermatologist Dr. Ellen Turner is encouraging her patients, as well as residents ... on skin safety and health now and in the future. , The dermatology-specific awareness ...
(Date:5/4/2016)... ... May 04, 2016 , ... Momsense, Inc. ... mothers. The company’s patented technology, The Smart Breastfeeding Meter, is designed to monitor ... the technology is now available for purchase at Target.com . , ...
(Date:5/4/2016)... ... ... Francesca Loparco, Co-Founder of Queen City Dream Cars, an exotic car rental ... at Christenbury Eye Center. The entrepreneur struggled with her computer, riding horses and ... as her in-office consultation and eye exam. Francesca’s eyesight was restored to 20/20 in ...
Breaking Medicine News(10 mins):
(Date:5/2/2016)... LAWRENCEVILLE, N.J. , May 2, 2016 /PRNewswire/ ... drug development company, today announced data from the ... dose escalating clinical trial (the OVATION Study) combining ... of care for the treatment of newly-diagnosed patients ... chemotherapy followed by interval debulking surgery.  In the ...
(Date:4/29/2016)... 2016  In the next ten years, the ... systems dependent on CRTs monitors to those reliant on ... Medical monitors and will automatically sync to existing ... foreseeable benefits to this technological advancement, it also ... to be replaced in order to be LCD ...
(Date:4/29/2016)... , April 29, 2016 ... for Life Sciences, Product Development Capabilities in ... Science Customer Base . Indegene ... today announced the acquisition of Skura Corporation,s life ... leader in adaptive sales enablement technology for life ...
Breaking Medicine Technology: